SCHEMBL25544293

SCHEMBL25544293

Cc1ccc2c(Cl)c(Br)cnc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.41
PARP1 P09874 1/20 0.41
PIM1 P11309 1/20 0.41
RPS6KA3 P51812 1/20 0.41
HTR1A P08908 2/20 0.39
ADRA1D P25100 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
TNF P01375 1/20 0.39
LMNA P02545 2/20 0.36
PSMB5 P28074 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PTGES O14684 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18283388 0.81 NR4A2 (0.46) LMNAKMT2ANPSR1MEN1MAPT
SCHEMBL437293 0.79 ACHE (0.43) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL23896032 0.78 GABRA1 (0.44) HTR1AADRA1DADRA1AADRA1BLMNA
SCHEMBL15215120 0.77 CHEK1 (0.41) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL9591539 0.75 MAOB (0.46) PARP1KDM4E
SCHEMBL29940962 0.74 NR4A2 (0.46) PARP1LMNANPC1RAB9AKMT2A
SCHEMBL25668139 0.74 NR4A2 (0.46) PARP1LMNANPC1RAB9AKMT2A
SCHEMBL15215112 0.73 ALDH1A1 (0.46) CHEK1PARP1PIM1RPS6KA3KMT2A
SCHEMBL25544291 0.73 ALDH1A1 (0.39) CHEK1PARP1PIM1RPS6KA3HTR1A
SCHEMBL6822558 0.73 MAOA (0.50) KMT2AKDM4EMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 CHEK1 4137/4885PARP1 847/4885PIM1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.